DUBLIN, June 3, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Anticoagulants Market in the US 2016-2020" report to their offering.
The report forecasts the anti-coagulants market in the US to grow at a CAGR of 6.67% during the period 2016-2020.
A trend to look forward to would be new therapeutic uses for anti-coagulant drugs. Using anticoagulants for purposes other than the normal anticoagulation effects will widen the scope of the market and help in gaining higher revenues. Heparin and related drugs are widely used for their anticoagulant activities. However, it has been identified that heparin exhibits anti-inflammatory activities and prevents the metastatic spread of tumor cells. Heparin exhibits anti-inflammatory activity by neutralizing cationic mediators, inhibiting adhesion molecules, and inhibiting heparanase, all of which are involved in leukocyte recruitment into tissues. Similarly, research studies indicate that heparins acts as an inhibitor of cell adhesion and thereby elicit anti-metastatic activities.
According to the report, a key growth driver would be the growing prevalence of coagulation disorders. Anticoagulants are prescribed in conditions such as AF, DVT, pulmonary embolism, stroke, clotting disorders, heart attack, and renal diseases. Cardiovascular disorders, kidney disorders, and strokes are becoming more prevalent due to unhealthy lifestyles among individuals, including a lack of physical activity, excessive alcohol consumption, and smoking.
It is estimated that 900,000 people are affected each year by DVT or pulmonary embolism, and 60,000-100,000 individuals die of this condition in the US. They are a major cause of maternal and hospital deaths in the US. Heart diseases are the leading cause of death in the region, with an estimated 610,000 deaths reported every year.
Further, the report states that one challenge that could hamper market growth is the side effects associated with drugs.
- Johnson & Johnson
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Daiichi Sankyo
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Anticoagulants: An overview
PART 06: Reimbursement scenario
PART 07: Anticoagulant reversal agents
PART 08: Approved anticoagulants in US
PART 09: Anticoagulants pipeline portfolio
PART 10: Market landscape
PART 11: Market segmentation by ROA
PART 12: Market segmentation by drug class
PART 13: Market segmentation by application
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
For more information visit http://www.researchandmarkets.com/research/5dvj9p/anticoagulants
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/anticoagulants-market-in-the-us-2016-2020---growing-prevalence-of-coagulation-disorders---research-and-markets-300279347.html
SOURCE Research and Markets